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ABSTRACT
Using Cytoplasmic Biopsies to Determine Bovine Oocyte Quality
by
Madison Lindsey
Utah State University, 2022
Major Professor: Dr. S. Clay Isom
Department: Animal, Dairy, and Veterinary Sciences
Embryos resulting from assisted reproductive technologies, such as in vitro fertilization
(IVF) or intracytoplasmic sperm injection (ICSI), develop with lower efficiencies than embryos
resulting from their in vivo counterparts. The reasons behind the developmental discrepancies
remain largely unknown. Because the oocyte is the primary determinant of embryo
developmental success, it is reasonable to consider inherent oocyte quality as a possible cause.
The hypothesis for this project is that there are distinct mRNA transcript patterns, or molecular
“fingerprints,” that distinguish high- versus low-quality oocytes developing within the same
environment. In this study, small cytoplasmic biopsies were removed from metaphase II (MII)
bovine oocytes via micromanipulation and utilized for relative transcript abundance profiling.
Preliminary experiments showed that oocyte developmental potential was unchanged after biopsy
(development to blastocyst after parthenogenetic activation was 26.7% for biopsied oocytes
versus 27.9% for control oocytes [P > 0.05]) and that biopsy mRNA content was highly
representative of the transcript levels in the oocytes those biopsies were derived from (average R2
= 0.8339 for quantitative PCR Ct values across 17 oocyte/biopsy couplets). For the next/main
experiment, 40 MII oocytes were biopsied and then parthenogenetically activated to stimulate

iv
development and cultured in vitro. Following an eight-day development period, embryos that
reached the blastocyst stage (success) and embryos that failed to develop were identified. This
was repeated five times, for a total of six experimental replicates (239 control oocytes and 240
biopsy oocytes). The relative transcript levels of 48 genes were evaluated in the oocyte biopsies
corresponding to successful and failed embryos using the BioMark qPCR system from Fluidigm.
The functional categories of the 48 genes include apoptosis, oocyte-specific, epigenetic,
metabolism, housekeeping, pluripotency, and RNA processing. After applying false discovery
rate (FDR) corrections to raw Ct and delta Ct data analyzed by ANOVA, none of the 48 genes
were significantly differentially expressed in biopsies from successful versus failed oocytes. In
conclusion, the evidence gathered to this point does not support the hypothesis of differential
transcript patterns between the cytoplasmic biopsies from oocytes of divergent developmental
success. However, this study provides technical innovation for future research of oocyte quality.
(71 pages)
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PUBLIC ABSTRACT
Using Cytoplasmic Biopsies to Determine Bovine Oocyte Quality

Madison Lindsey
Embryos resulting from assisted reproductive technologies, such as in vitro fertilization (IVF) or
intracytoplasmic sperm injection (ICSI), develop with lower efficiencies than embryos resulting
from their in vivo counterparts. The reasons behind the developmental discrepancies remain
largely unknown. Because the egg is the primary determinant of embryo developmental success,
it is reasonable to consider inherent egg quality as a possible cause. The hypothesis for this
project is that there are distinct mRNA transcript patterns, or molecular “fingerprints,” that
distinguish high- versus low-quality eggs developing within the same environment. In this study,
a small cytoplasmic biopsy was removed from 40 eggs and stored for later use. The eggs were
chemically activated to stimulate development in the absence of sperm and cultured in vitro.
Following an eight-day development period, embryos that reached the blastocyst stage (success)
and embryos that failed to develop were identified. This was repeated five times, for a total of six
experimental replicates. The relative transcript levels of 48 genes were evaluated in the egg
biopsies corresponding to successful and failed embryos using quantitative PCR. Analysis of the
qPCR data revealed no significant differences in levels of transcripts for any of the 48 genes
between the successful and failed development groups. Therefore, the evidence does not support
differential expression between the cytoplasmic biopsies from oocytes of divergent
developmental success. However, this study provides technical innovation for future research of
oocyte quality.
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REVIEW OF LITERATURE

Infertility
Estimates suggest that approximately 186 million people worldwide currently struggle
with infertility (Szamatowicz 2016). In fact, out of all couples within the reproductive age range,
approximately 15% struggle to conceive (Sun, Gong et al. 2019). A couple’s lack of ability to
conceive can be rooted in either the male or the female, and there are many potential causes for
infertility or subfertility in either sex.
In about 50% of infertility cases, the man is at least partially responsible (Leslie, Siref et
al. 2020). Hormone imbalances are a major contributor to male infertility and occur when the
hypothalamic-pituitary-gonadal (HPG) axis is disrupted. Usually, hypogonadism results, which is
insufficient production of reproductive hormones needed for the reproductive system to function
properly. Often, the cause of the hormone imbalance is non-congenital, such as obesity, excessive
exogenous testosterone use, opioid use, psychotropic drug use, or radiation treatments (Leslie,
Siref et al. 2020). Additionally, there are various urogenital abnormalities that can cause
infertility such as cryptorchidism, absence of the epididymis, and varicoceles. Exposure to toxins,
like pesticides, or infections, like chlamydia or tuberculosis, can also impact fertility. Finally,
some important genetic mutations to mention are Y chromosome microdeletions, which can cause
azoospermia, and the cystic fibrosis transmembrane conductance regulator mutation, which is
associated with congenital bilateral absence of the vas deferens (CBAVD), preventing proper
ejaculation of sperm (Leslie, Siref et al. 2020, Rodrigues, Polisseni et al. 2020). Some genetic
disorders, such as Klinefelter syndrome, Kallmann syndrome, or Prader-Willi syndrome can also
cause infertility by affecting the HPG axis, leading to hormone imbalance (Leslie, Siref et al.
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2020, Rodrigues, Polisseni et al. 2020). All of these issues mentioned, as well as many more not
specified here, can contribute to infertility in the male.
Other times, the issue of infertility stems from the female or both the female and male
simultaneously. Approximately 37% of the cases are due to the female alone, and an additional
35% involve both sexes (Walker and Tobler 2020). Just like in males, there are a host of different
issues that can lead to infertility in women. Some of the factors influencing fertility are shared
between the sexes, such as certain genetic disorders, obesity, infections, and toxins (Walker and
Tobler 2020). Oligo-ovulation, which is infrequent ovulation, and anovulation, the lack of
ovulation, are both common problems seen in women. These can be a result of several situations.
First, this can happen due to being underweight, which can cause hypogonadism by reducing
gonadotropin-releasing hormone (GnRH). Another possible cause is polycystic ovarian syndrome
(PCOS), associated with high levels of anti-Müllerian hormone (AMH). Ovarian insufficiency
can also cause anovulation due to lack of oocytes. This naturally occurs with age as oocyte
numbers and quality decline. However, it can occur early in women that smoke cigarettes or that
have certain genetic diseases, like Turner syndrome (Rodrigues, Polisseni et al. 2020, Walker and
Tobler 2020). Some other common causes of infertility, that are not due to anovulation, include
endometriosis, pelvic inflammatory disease (PID), and uterine septa (Walker and Tobler 2020).
A common reason for females resorting to reproductive technologies to conceive is
decreased fertility due to age. The number of couples that are choosing to delay parenthood in
developed countries has been increasing over the past few decades (Schmidt, Sobotka et al.
2011). This is likely due to several different changes that have occurred. First, use and availability
of contraceptives, such as pills or hormonal implants, have increased so that the option exists for
individuals to remain sexually active with little chance of becoming pregnant. Another important
factor that is likely contributing to delayed parenthood is the increase in delayed marriage as well
as divorce rates. Additionally, gender equality has contributed to this change, since more women
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are making work and higher education a priority over marriage and/or childbearing (Schmidt,
Sobotka et al. 2011).
Animals can have many of the same causes of infertility as humans. Aging can lead to a
decrease in fertility, but because livestock have short lifespans, they do not experience
menopause as humans do. This is because their oocyte supply is not depleted in their lifespan.
Apart from humans, only a few other species of mammals have menopause, including some
primates and toothed whales (Walker and Herndon 2008, Johnstone and Cant 2019). Other
sources of infertility seen in livestock include obesity, genetic defects, toxin exposure, infection,
and injury. Just as in humans, being overweight can impact the body’s reproductive system. For
example, in bulls, obesity can result in reduced libido and ability to regulate the temperature of
the testicles. On the other hand, undernourishment or being underweight can delay puberty in
both females and males and reduce fertility of post-pubertal animals (Van Camp 1997). The
impact of nutrition and hormone imbalance on the reproductive system can be clearly seen in the
dairy cattle industry. Following parturition, the cow begins lactating, which requires high
amounts of energy, but she cannot consume enough to meet those needs. Because of this, cows
often have a negative energy balance during this time, which affects secretion of necessary
reproductive hormones like GnRH and progesterone and lowers her ability to conceive again
soon after giving birth (Siatka, Sawa et al. 2018).
Many of the genetic defects that are seen in humans can also occur in animals. However,
some species are more prone to certain defects than others. For instance, cryptorchidism, which is
the failure of one or both testes to descend into the scrotum, was mentioned earlier as a cause for
human male infertility and can occur in cats, dogs, pigs, cattle, and sheep as well (Van Camp
1997, Amann and Veeramachaneni 2007, Senger 2012). Chromosomal disorders equivalent to
Turner and Klinefelter Syndrome in humans have been shown to occur in horses and result in
infertility, though they are rare (Raudsepp 2020). As mentioned earlier, exposure to certain
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toxins, like cadmium and mercury, can negatively impact reproduction, and this holds true in
female and male animals as well (Massányi, Massányi et al. 2020).
Some common issues seen in cattle include endometritis and ovarian cysts. Additionally,
heat is an important cause of infertility or subfertility in livestock animals, especially during the
summer months since they are often outside with limited protection from the weather. High
temperatures, especially when combined with humidity, can lead to heat stress. High
temperatures are associated with higher proportions of abnormal sperm in males (Parrish,
Willenburg et al. 2017). In females, heat stress leads to reduced feed intake as well as decreased
GnRH secretion, causing subfertility and decreasing conception rates (De Rensis, Lopez-Gatius et
al. 2017). Finally, dairy cattle are well known for having decreased fertility due to the high
energy demand of producing large quantities of milk. This can result in a negative energy
balance, which disrupts GnRH secretion just as heat stress does (Siatka, Sawa et al. 2018).
Although recent data seems to be lacking, a report from 2002 suggested that infertility in
the cattle industry led to approximately $500 million losses in both the beef and dairy industries
annually, for a total of about $1 billion per year in the combined cattle industries (Bellows, Ott et
al. 2002). These numbers have likely changed over the last 20 years, but it remains clear that
infertility leads to significant financial loss for livestock producers.

Assisted Reproductive Technologies
Assisted reproductive technology (ART) is a commonly used therapy to combat these
fertility issues, particularly in humans, when simple treatments, such as administration of
antibiotics or hormones, is not a solution. For example, when infertility is caused by genetic
diseases or age, ART can sometimes improve the chances of achieving a pregnancy. These
technologies are also applied to create more offspring from high-producing livestock in shorter
time intervals and for conservation efforts of some endangered species or zoo animals. There are
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several different technologies that can be used, including artificial insemination (AI), intrauterine
insemination (IUI), in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and
somatic cell nuclear transfer (SCNT).
Artificial insemination is one of the simplest and first assisted reproductive technologies
applied in livestock (Moore and Hasler 2017). The procedure was first performed in the dog by
Lazzaro Spallanzani in 1784. Later, in 1897, Walter Heape reported successful application of AI
in dogs, rabbits, and horses. The use of AI was then applied in cattle in the early 1900s in Russia
and in Denmark (Ivanoff 1922, Ombelet and Van Robays 2015). Originally, semen was deposited
into the vagina the same as natural service would. However, it was discovered in 1937 that higher
pregnancy rates are accomplished when semen is deposited directly into the uterus with the
rectovaginal method that is still used today in the cattle industry (Moore and Hasler 2017).
Because the semen does not need to travel through the cervix, smaller quantities of semen can be
used successfully. Soon after, it was also discovered that semen could be cooled and shipped. In
the late 1940s, cryopreservation of semen was successfully achieved (Moore and Hasler 2017).
These methods of preserving semen for longer periods of time allow for the sperm to be
transported and used at other locations for AI. The adoption of AI into the equine, cattle, and
other livestock industries has allowed genetically superior sires to produce more offspring
without requiring the sire to be present for breeding (Moore and Hasler 2017).
In humans, AI is often referred to as intrauterine insemination (IUI). This procedure can
be utilized to achieve pregnancy in certain infertility situations, such as mild male factor
infertility, endometriosis, or unexplained infertility. The procedure requires a catheter to be
inserted through the cervix in order to deposit the semen directly into the uterus. The natural
menstrual cycle may be utilized for some women, but others may need to follow a hormone
protocol for superovulation to increase the chances of pregnancy (Starosta, Gordon et al. 2020).
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In more severe cases of infertility, IVF or ICSI may be more successful than IUI. In vitro
fertilization has been used to help couples overcome infertility for over 40 years. The first human
IVF baby was Louise Brown, born in 1978 (Sirard 2018). IVF involves the mixing of sperm and
oocytes together in a dish, allowing the sperm to fertilize the oocytes outside of the body. This
increases chances of fertilization because it eliminates the process of the sperm traveling through
the cervix and up through the oviduct. Thus, there is a higher concentration of sperm that have
access to the oocytes. However, when the issue stems from male factor infertility,
intracytoplasmic sperm injection (ICSI) is often recommended. This procedure, which appeared
in the early 1990s, involves the injection of a sperm cell into the cytoplasm of an oocyte and can
be useful in cases where the male is not producing enough sperm or has many abnormal sperm
that struggle to successfully fertilize (Rosenwaks and Pereira 2017).
These technologies, especially IVF, are applied commercially in livestock industries
including dairy, beef, goat, and sheep. Originally, the purpose of these procedures was to
overcome infertility in the animals as well. However, now they are utilized with the purpose of
improving genetics and reducing the generation interval, especially in larger species that require
more time to reach sexual maturity. With advances in genetic testing and the ability to sex semen,
producers have more control than ever regarding the production of elite offspring (Sirard 2018).
Horses are an exception to this, as success with IVF has yet to be consistent and effective. ICSI
can be used in horses though, and specialized labs exist that will perform ICSI commercially
(Lazzari, Colleoni et al. 2020).
Lastly, somatic cell nuclear transfer (SCNT), or cloning, is available. This technology
involves the removal of the nucleus from an oocyte followed by fusion of that oocyte to a somatic
cell nucleus. Although not widely adopted due to cost and low efficiency, cloning is occasionally
used in the food industry on elite beef and dairy cattle. The primary purpose is to produce more
breeding stock of superior quality within the industries (Tanne 2008). However, consumption of
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the meat and milk products from clones is safe and approved by the FDA (FDA 2021). Cloning
is also used in research as well as for production of superior rodeo stock, including both rodeo
bulls and bucking horses. There are also companies available that will clone pets, including dogs,
cats, and horses (Sinogene 2020).
Some of these technologies may also be useful tools to aid in conservation of endangered
species. There are several advantages that ART could provide to the species at risk. First, for
species in which the technology exists, production of embryos in the lab can use cryopreserved
sperm and oocytes, which means that individual animals do not need to be transported in order to
breed. It also saves animals from the risk of injury due to potential conflict. Another important
advantage of cryopreservation is that if zoos have limited space, embryos or gametes can be
stored for future use, and gametes or somatic cells may be collected from non-captive individuals
to introduce genetic diversity that is essential for population sustainability. However, each species
has biological differences regarding reproduction, and the existing protocols for ART have been
developed for humans, livestock, and rodents rather than rare species like those that are
endangered and in zoos. Therefore, a significant amount of research is still required to understand
each species before the technologies can be successfully used for conservation efforts (Herrick
2019).

Folliculogenesis
The process through which an ovarian follicle grows from an immature state to a mature
follicle is referred to as folliculogenesis (Senger 2012). Each follicle found on the ovary consists
of a single oocyte surrounded by one or more layer of cells. The process of folliculogenesis can
be divided into two consecutive phases. The first is the preantral phase which begins with the
primordial follicle that progresses into a primary follicle and then a secondary follicle. The
second phase is the antral phase, characterized by the presence of an antrum, a cavity filled with
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follicular fluid. The antral phase includes the tertiary and the preovulatory follicle, also referred to
as a Graafian follicle (Araújo, Gastal et al. 2014, Gershon and Dekel 2020).
The primordial follicle has only one layer of flat, pre-granulosa cells encompassing the
oocyte. At this stage, the follicles are quiescent and make up the reserve pool of follicles.
However, the majority of these follicles remain and die at this stage, as relatively few are
activated in order to progress past this step (Araújo, Gastal et al. 2014, Shah, Sabouni et al. 2018).
In follicles that do undergo follicular activation, the granulosa cells begin to change from flat to a
cuboidal shape and begin to proliferate. The oocyte within also begins to grow. This process of
activation is irreversible and must be regulated to avoid early depletion of follicles (Araújo,
Gastal et al. 2014). Once the single layer of granulosa cells has completely transformed from flat
to cuboidal, the follicle is considered a primary follicle. The follicle then transitions into a
secondary follicle as the granulosa cells continue to divide and form a second layer surrounding
the oocyte. During this stage, the oocyte begins secreting material that results in formation of a
translucent layer around its plasma membrane, known as the zona pellucida (Senger 2012).
Meanwhile, a new layer of cells develops, called theca cells (Araújo, Gastal et al. 2014, Shah,
Sabouni et al. 2018). The theca cells begin separating into two layers: the theca interna and theca
externa which produce androgens that the granulosa cells then convert to estrogen (Gershon and
Dekel 2020). The steps of follicular development up to this stage are slow and take approximately
a year to complete (Conti and Chang 2016).
As the follicle grows and granulosa cells continue to proliferate, a pocket of fluid, known
as the antrum, begins to form within the layers of granulosa cells. At this point, the follicle has
entered the antral phase and is identified as a tertiary or early antral follicle (Araújo, Gastal et al.
2014). As the antrum forms, the granulosa cells that remain near the oocyte are referred to as the
cumulus granulosa cells (often, “cumulus cells”, for short), and those that remain associated with
the wall of the follicle are referred to as mural granulosa cells. Most of the follicles that are
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activated will undergo atresia before they reach this stage (Gershon and Dekel 2020). However, a
few are recruited to continue growing under the influence of follicle stimulating hormone (FSH)
that is released from the anterior pituitary. As the follicles grow, they begin secreting estrogen,
which has a negative feedback effect on FSH levels. Follicles that become dominant are no longer
FSH-dependent and start to secrete inhibin, which further suppresses FSH levels. This drop in
FSH results in the death of follicles that were still reliant on FSH for their development, while the
dominant follicle thrives (Senger 2012). Dominant follicles are candidates for ovulation, in which
the follicle ruptures to allow the release of the oocyte, under the proper endocrine conditions. The
antral phase of follicular development is much more rapid than the preantral phase and is
completed in only 40 to 50 days for follicles that survive (Conti and Chang 2016).

Oogenesis
The process through which an oocyte develops and matures to reach developmental
competence and be suitable for fertilization is known as oogenesis. Oocytes develop from
primordial germ cells (PGCs) which are located in the yolk sac of the developing fetus. These
PGCs must then migrate, during the first trimester of gestation, to the genital ridge that will
become the ovary or testis (Senger 2012). This event occurs in both sexes (Edson, Nagaraja et al.
2009). At this time, sex determination begins and is based on the presence or absence of the SRY
gene found on the Y chromosome. In the absence of this SRY gene, as seen in chromosomally
normal (XX) females, ovaries will develop (Sánchez and Smitz 2012).
Primordial germ cells in the ovary will enter into a mitotic phase in which they proliferate
and form germ cell cysts or nests of oogonia (Arroyo, Kim et al. 2020). Following the
proliferative phase, the oogonia begin meiosis. During prophase I of meiosis, the oocyte
progresses through the leptotene, zygotene, and pachytene stages before entering the diplotene
stage where it arrests until it either dies or is recruited to develop further after puberty is reached
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(Sánchez and Smitz 2012, Arroyo, Kim et al. 2020). Follicle formation is also beginning at this
time of arrest, surrounding the primary oocytes with pre-granulosa cells in order to form
primordial follicles (Arroyo, Kim et al. 2020). With each ovarian cycle, as follicles are recruited
to grow, the primary oocyte within the follicle grows as it synthesizes and retains many RNAs
that are vital for proper maturation and early embryo development. This is an important part of
molecular and cytoplasmic maturation of the oocyte. Cytoplasmic maturation involves the
cessation of transcription and translation within the oocyte and re-distribution of organelles, while
molecular maturation involves the oocyte acquiring certain mRNAs and proteins just prior to
ovulation. These mRNAs and proteins are associated with the intrinsic quality of the oocyte
(Sirard, Richard et al. 2006). Meiotic (nuclear) maturation must also occur. Nuclear maturation is
initiated by the LH surge associated with ovulation and involves germinal vesicle breakdown
(GVBD), in which the nuclear membrane is degenerated. This allows meiosis to resume, leading
to the extrusion of the first polar body (Sánchez and Smitz 2012, Arroyo, Kim et al. 2020). The
oocyte is known as a secondary oocyte at this stage, and it immediately enters meiosis II, where it
arrests at the metaphase stage until fertilization occurs (Arroyo, Kim et al. 2020).
The release of the oocyte from the follicle during ovulation then allows the oocyte to
travel down through the oviduct, or fallopian tube, where fertilization will occur if sperm is
present. If the oocyte does get fertilized, that triggers resumption of meiosis II, extruding a second
polar body (Arroyo, Kim et al. 2020).

Mechanism of Meiotic Arrest and Resumption
Maturation promoting factor (MPF) is a multi-subunit molecular complex that is involved
in both meiosis and mitosis of cells and plays an important role in resumption of meiosis during
oogenesis (Edson, Nagaraja et al. 2009). The MPF complex is composed of two separate proteins:
cyclin B and cyclin-dependent kinase 1 (CDK1), which may also be called CDC2 (Bhattacharya,
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Basu et al. 2007). Prior to the preovulatory stage, there are not high enough levels of CDK1 for
resumption to occur, but as the follicle nears ovulation the oocyte begins to express higher levels
of CDK1 (Jaffe and Egbert 2017).
In order to prevent release from meiotic arrest too early, the MPF must remain in an
inactive form until the LH surge occurs, which will trigger ovulation (Edson, Nagaraja et al.
2009). The MPF complex is deactivated by phosphorylation of Thr14 and Tyr15 by
WEE1/MYT1 protein kinases and dephosphorylation of Thr161 of CDK1 (Tiwari and Chaube
2017). In this state, it is sometimes referred to as pre-MPF. On the other hand, CDC25 activates
MPF by reversing these phosphorylation events (Bhattacharya, Basu et al. 2007).
High levels of cyclic AMP (cAMP) also play an important role in maintenance of the
meiotic arrest by controlling the phosphorylation of WEE1B via protein kinase A (PKA), which
in turn, affects phosphorylation of CDK1. Cyclic GMP (cGMP) diffuses into the oocyte via gap
junctions and helps maintain the high levels of cAMP by inhibiting cAMP phosphodiesterase
activity, primarily by inhibiting the enzyme PDE3A (Jaffe and Egbert 2017). Once the LH surge
occurs, MPF is activated and cGMP levels drop as cGMP diffuses out of the oocyte, allowing
meiosis to resume. This leads to GVBD, condensation of chromosomes, and the first meiotic
division, resulting in the extrusion of the first polar body and the completion of meiosis I (Edson,
Nagaraja et al. 2009, Arroyo, Kim et al. 2020).
The oocyte then enters the second round of meiosis and arrests in metaphase II until the
time of fertilization (Arroyo, Kim et al. 2020). The mechanism by which MPF maintains the
arrest at this stage varies from that seen in the first arrest. Cytostatic factors (CSFs) are required
to maintain stable MPF by preventing degradation of the cyclin B. When cyclin B is degraded by
anaphase promoting complexes (APC), CDK1 is then dephosphorylated at Thr161 and
phosphorylated at Thr14 and Tyr 15, which deactivates the MPF, as mentioned previously
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(Tiwari and Chaube 2017). This destabilization occurs at fertilization and allows for meiosis II to
be completed (Edson, Nagaraja et al. 2009).

Fertilization and Oocyte Activation
In order for embryo development to occur, the oocyte must undergo activation. This
releases the oocyte from the metaphase II arrest and allows for embryo development to begin
(Canel, Bevacqua et al. 2010). This process is initiated by the entry of sperm into the oocyte as
the sperm-derived enzyme phospholipase C-zeta (PLCζ) causes calcium (Ca+2) oscillations. The
enzyme cleaves lipid phosphatidylinositol 4,5-biphosphate (PIP2) to generate diacylglycerol
(DAG) and inositol 1,4,5-triphosphate (IP3). Receptors for IP3 reside in the endoplasmic
reticulum, the calcium- storage organelle of the oocyte. Thus, when IP3 binds to the endoplasmic
reticulum, it causes release of Ca+2. The Ca+2 then also begins to bind to receptors found in the
endoplasmic reticulum, leading to more Ca+2 being released, and this process spreads like a wave
throughout the oocyte causing the Ca+2 oscillations.
Parthenogenetic embryos, which lack a paternal genome, can be produced by artificially
inducing activation. In cattle, chemical activation is often used which utilizes a Ca+2 ionophore,
such as ionomycin. However, ionomycin cannot induce Ca+2 oscillations, only a single peak in
Ca+2, by increasing the permeability of the cell membrane to calcium ions. The high level of Ca+2
temporarily inactivates MPF and mitogen-activated protein kinase (MAPK). The ionomycin must
then be followed by a second treatment to maintain low MPF activity and allow for embryo
development. Cycloheximide (CHX) and/or 6-dimethylaminopurine (DMAP) are often employed
as the secondary treatment. Cycloheximide causes low MPF activity by disrupting the balance of
cyclin B, a major component of MPF that regulates its activity. The protein kinase inhibitor,
DMAP, targets many different components involved with the process of activation in order to
decrease MPF and MAPK activity. Parthenotes created utilizing DMAP have a diploid
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pronucleus rather than a haploid pronucleus because DMAP causes destruction of the metaphase
plate, inhibiting the extrusion of the second polar body. However, the secondary treatment is
associated with high rates of blastocyst development.

Embryo Development
Once an oocyte has been fertilized by a sperm, the female and male pronuclei must fuse
in order to form a zygote, or single-celled embryo. The embryo then begins to go through a series
of cleavage divisions, in which the size of the cells becomes progressively smaller with each
division while the overall size of the embryo remains the same (Senger 2012). The first division
results in a 2 -cell embryo, another division results in a 4-cell, then an 8-cell embryo all while
traveling down the oviduct toward the uterus (Lonergan, Fair et al. 2016). Each individual cell
within the zona pellucida is known as a blastomere.
The timing of cleavage events and stage at which the embryo enters the uterus varies
between species. Both cows and women reach the 2-cell stage by approximately 24 hours
following ovulation, but a sow reaches this stage even earlier at around 14-16 hours postovulation (Senger 2012). The embryo enters the uterus at approximately the 16-cell stage, which
occurs on day 4 of pregnancy, in cattle (Lonergan, Fair et al. 2016). Following this stage of
development, the cells begin to compact and the blastomeres can no longer be distinguished from
one another, at which point the embryo is then considered to be a morula. This is the first stage at
which differences between cells begin to arise. Gap junctions form between inner cells of the
embryo while tight junctions form between the outer cells, which allow for intercellular
communication and altered permeability, respectively.
Once the junctions have been established, an active sodium pump located in the outer
cells causes fluid to enter the embryo and begin forming a fluid cavity called a blastocoele. As the
blastocoele expands and becomes noticeable, the morula transitions into a blastocyst, which
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typically occurs around day 6-8 in cattle and days 5-6 in humans (Pfeffer and Pearton 2012,
Senger 2012, Martins, Nastri et al. 2017). At this stage of development, the inner cells are
referred to as the inner cell mass (ICM) and will give rise to the embryo proper, while the outer
cells are called the trophoblast which will develop into the extraembryonic components of the
placenta (Pfeffer and Pearton 2012). As the blastomeres continue to undergo mitosis and the
blastocoele grows, pressure begins to build within the zona pellucida. The blastocyst also begins
to collapse and expand intermittently. During this time, the trophoblast cells also produce
proteolytic enzymes that begin destroying the zona pellucida. These factors combined eventually
lead to the blastocyst hatching from the zona pellucida, which is typically seen at approximately
days 9-11 post-fertilization (Rodríguez-Alonso, Sánchez et al. 2020).
Once the embryo has completely hatched, it undergoes a series of morphological changes
and becomes filamentous, or threadlike, when it is fully elongated. At about day 19 the
filamentous embryo begins attaching to the endometrial luminal epithelium. This process is called
implantation (Lonergan, Fair et al. 2016). Soon after, recognition of pregnancy must occur in
order to maintain the pregnancy and allow for continued growth and development of the fetus
(Senger 2012).

The Maternal-to-Embryonic Transition
Initially an embryo must rely on the transcripts that were stored up in the oocyte prior to
fertilization because the incipient embryonic genome is quiescent during the first several mitotic
cell cycles of embryogenesis (Lee, Bonneau et al. 2014). However, after several cleavage
divisions, the embryo requires new transcripts and no longer needs certain maternal transcripts.
The maternal-to-embryonic transition (MET) encompasses three separate events that must occur
in order for the embryo to begin synthesizing transcripts and continue developing: clearance of
maternal transcripts, replacement of specific maternal transcripts, and embryonic genome
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activation (EGA) to synthesize new transcripts not provided by the oocyte (Schultz 2002, Graf,
Krebs et al. 2014).
Maternal clearance occurs through both a maternal and embryonic mode. The maternal
mode is initiated by maternal factors, while embryonic mode relies on de novo transcription from
the embryo (Lee, Bonneau et al. 2014). There is evidence that microRNAs (miRNAs) from the
embryo contribute to depletion of the maternal transcripts. Other methods exist as well, including
signaling pathways that result in activation of clearance mechanisms and RNA-binding proteins
that help direct degradation machinery to the proper mRNAs (Graf, Krebs et al. 2014).
Because the embryo genome is transcriptionally quiescent at first, nuclear
reprogramming, resulting in EGA, is required before the embryo can begin synthesizing
transcripts of its own. Products stored in the oocyte allow for epigenetic modifications to be
made, either to histone proteins or DNA, resulting in changes to the chromatin structure. These
alterations provide transcription factors, which are also supplied from the oocyte along with RNA
Polymerase II, access to the genome (Graf, Krebs et al. 2014). Together, these components lead
to EGA and transcription of embryonic genes. Many of the transcripts are embryo-specific and
are necessary to prepare the embryo for future developmental events, such as gastrulation and
differentiation. Other transcripts are synthesized to replace maternal RNAs being depleted that
are required for basic cellular functions (Schultz 2002, Lee, Bonneau et al. 2014). EGA takes
place at different developmental stages across species. In cattle, EGA occurs at approximately the
8- to 16-cell stage but at the 4- to 8-cell stage in humans and swine; it is considered to be the most
important event that occurs during early embryo development prior to implantation (Gad, Hoelker
et al. 2012, Graf, Krebs et al. 2014).
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Measures of Oocyte and Embryo Quality
Oocyte Quality
Oocyte and embryo quality are closely associated. There is a large body of evidence
suggesting that the primary factor that determines an embryo’s ability to develop to the blastocyst
stage and beyond is the intrinsic quality of the oocyte (Lonergan, Rizos et al. 2003, Roberts 2005,
Sirard, Richard et al. 2006, Lechniak, Pers-Kamczyc et al. 2008). In order for an oocyte to be of
high quality, it must mature properly. According to Sirard et al. (Sirard, Richard et al. 2006),
there are three types of oocyte maturation: meiotic maturation, cytoplasmic maturation, and
molecular maturation. Meiotic maturation involves resumption of meiosis and the extrusion of the
first polar body following the LH surge or aspiration from the follicle. Cytoplasmic maturation
occurs prior to meiotic maturation and includes the cessation of protein and RNA synthesis and
the depletion of ribosomes from the oocyte. This type of maturation also involves the
redistribution of mitochondria and cortical granules that occurs near the LH surge. Finally,
molecular maturation, which is often discussed as a part of cytoplasmic maturation, consists of
stockpiling of certain molecules, like RNAs or proteins, that are required for successful
fertilization. This is often referred to as oocyte capacitation. However, many of these molecules
remain unidentified (Sirard, Richard et al. 2006).
Studies have shown that oocytes that undergo meiotic maturation and extrude the first
polar body sooner tend to be larger in size and are more likely to cleave and develop into a
blastocyst as an embryo than those that mature later. Larger oocytes (>120 µm) also appeared to
be more chromosomally normal compared to smaller oocytes. Furthermore, mitochondrial DNA
(mtDNA) copy number of the oocyte is another factor that appears to be positively correlated
with cleavage rates (Lechniak, Pers-Kamczyc et al. 2008).
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The success of the oocyte’s cytoplasmic and molecular maturation may be reflected in
the abundance of transcripts that are stockpiled. Oocytes with greater amounts of these transcripts
are associated with superior morphology and higher blastocyst rates. Not only is the quantity of
transcripts important, but also their levels of polyadenylation, which impacts the stability of those
maternal transcripts necessary for early embryo development (Lonergan, Rizos et al. 2003,
Lechniak, Pers-Kamczyc et al. 2008). Different patterns in the polyadenylation of the maternal
transcripts have been observed between embryos that cleave early and those that cleave late
(Lechniak, Pers-Kamczyc et al. 2008). It has also been shown that polyadenylation can be
affected by the maturation media (Lonergan, Rizos et al. 2003).
While some of these benchmarks for successful oocyte development can be observed, the
most important aspects are invisible to our eyes. It remains largely unknown what exactly is
required for an oocyte to be of good quality. The only definitive indication that an oocyte is of
good quality is proper fertilization and the development of a healthy offspring (Sirard, Richard et
al. 2006).
Embryo Quality
The timing of the first cleavage division of an embryo is indicative of the oocyte and
embryo competence. This cleavage event typically occurs between 22 and 48 hours post
insemination (hpi) in cattle or 22 and 30 hpi in humans. Embryos that cleave early are associated
with many positive characteristics including higher blastocyst rates, blastomere numbers, and
vitrification survival rates along with lower apoptotic cell ratios and rates of fragmentation
(Lechniak, Pers-Kamczyc et al. 2008). Total cleavage rates (including early and late cleaving
embryos) tend to be high, around 80% (Lonergan, Rizos et al. 2003, Camargo, Costa et al. 2019).
The ability of an embryo to progress to the blastocyst stage is the next key indicator of a
high-quality oocyte and embryo. Significantly fewer embryos reach this stage compared to the 2-
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cell or cleavage stage embryo. Approximately 30-40% of oocytes that are matured, fertilized, and
cultured in vitro develop into blastocysts (Lonergan, Rizos et al. 2003, Sirard, Richard et al.
2006). Many of the embryos that do not reach the blastocyst stage are blocked at the MET,
perhaps because they fail to successfully activate the embryonic genome. Quality of blastocysts
can then be assessed by cell number, trophectoderm to inner-cell mass ratio, overall appearance
and size, and expansion of the blastocoele (Sirard, Richard et al. 2006).
Embryo transfer is often performed at or before the blastocyst stage. Therefore, the
subsequent evaluation of quality comes from the embryo’s ability to successfully induce a
pregnancy. Some blastocysts are of higher quality than others and are more likely to result in a
pregnancy. However, there are many factors that contribute to this step, including proper uterine
environment of the recipient or patient, which requires an effective hormone protocol. Other
issues can affect the uterine environment as well, such as genetics and certain diseases.
Additionally, in vitro matured oocytes that develop to the blastocyst stage continue to have lower
pregnancy rates compared to blastocysts originating from in vivo matured oocytes, perhaps due to
differences in the culture environment or removal of the oocyte from the follicle prior to the LH
surge (Sirard, Richard et al. 2006).
The final sign of a high-quality embryo and oocyte is development to term and the birth
of healthy offspring. One issue that is directly related to the production of the embryos in vitro is
Large Offspring Syndrome (LOS), which can occur in response to certain in vitro culture
conditions, such as high serum concentrations in the media (Lonergan, Rizos et al. 2003, Sirard,
Richard et al. 2006).

Single-cell Gene Expression Analysis
Technology over the last four decades has improved drastically to allow for analysis of
DNA and RNA on increasingly smaller samples. A major area of application of this technology,
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in the production of in vitro embryos, is preimplantation genetic testing (PGT) which began
increasing in popularity in the early 2000s. This genetic screening is typically achieved via a
small biopsy of trophoblast cells from a blastocyst embryo, or approximately a 5-day embryo in
humans (Johnson 2019). Certain single-nucleotide polymorphisms (SNPs) and aneuploidy can be
detected to help avoid selection and transfer of embryos containing mutations or genetic diseases
(Johnson 2019, Paolillo, Londin et al. 2019). Significant advances in polymerase chain reaction
(PCR) have played a large role in this technology.
The first experiments utilizing PCR emerged in the early 1980s (Kuypers and Jerome
2017), and about a decade later, quantitative PCR (qPCR) became available, which incorporated
fluorescent dyes or probes to measure quantity in real-time throughout the amplification (Zhu,
Zhang et al. 2020). There are several platforms available for qPCR in which samples are loaded
into wells of a microfluidic-based chip, which reduces the time required to complete the reactions
(Zhu, Zhang et al. 2020). During qPCR, each sample obtains a threshold cycle (Ct) value that
reflects the number of cycles completed before the sample reaches a specific threshold quantity.
Using this information and a standard curve, the quantities of original sample can be calculated.
This protocol may also be applied to RNA experiments if reverse transcription (RT) is performed
first, creating cDNA from the RNA templates (Zhu, Zhang et al. 2020). This was, and remains, a
necessary step due to the relatively fragile nature of RNA compared to DNA.
These technologies can successfully be performed on very small quantities of starting
nucleic acid material, such as that found in a single cell. More recently still has been the
development of single cell genomics and with it, many variations of sequencing technologies.
The advantage with DNA- or RNA-sequencing over qPCR is that it allows for investigation into
all genes or transcripts, rather than a subpopulation of them. It also allows for detection of minor
variations of genomes or transcriptomes between cells. Analyzing single cells makes it possible
for scientists to gain a more detailed understanding of the differences that exist between cell
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types, as well as how those differences may contribute to a cell’s particular role in a tissue.
Variation can be found even amongst cells of the same type (Paolillo, Londin et al. 2019).
It is important to understand the differences between analyzing the genome (DNA) and
the transcriptome (RNA). A single somatic cell contains an average of 9 pg of DNA compared to
10-60 pg of RNA, of which only about 4% is mRNA (Wu, Xiao et al. 2014, Paolillo, Londin et
al. 2019). The analysis of the genome and the transcriptome each has its purpose. For example,
PGT requires examination of the DNA itself, using just a few cells, for possible mutations that
may not be expressed as RNA at that time. On the other hand, to investigate maternal transcripts
of the oocyte, mRNA is the target of analysis.
Previously, to evaluate oocyte transcripts, lysis of the oocyte(s) was necessary, which
prevents any further development. Instead, we proposed taking a biopsy from each oocyte
cytoplasm with the intent to preserve embryo development potential. Our hypothesis for this
project is that distinct molecular “fingerprints” (mRNA expression patterns) exist that distinguish
between oocytes of high versus low developmental potential. To test this hypothesis, we analyzed
and compared transcript levels from biopsies of oocytes that successfully reached the blastocyst
stage following parthenogenetic activation to biopsies of oocytes that failed to develop to the
blastocyst stage.
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USING CYTOPLASMIC BIOPSIES TO DETERMINE BOVINE OOCYTE QUALITY

INTRODUCTION

It is well established that embryos produced in vitro using assisted reproductive
technologies (ART), such as in vitro fertilization (IVF) or intracytoplasmic sperm injection
(ICSI), usually result in lower blastocyst development and pregnancy rates compared to their in
vivo counterparts (Sirard, Richard et al. 2006, Ealy, Wooldridge et al. 2019). Although the
specific components contributing to the discrepancy in development rates are unknown, the
intrinsic quality of the oocyte is suspected because it plays a primary role in determining
blastocyst rates (Lonergan, Rizos et al. 2003).
There are several factors that determine the quality of an oocyte. Some of these factors
can be assessed visually, including morphology and extrusion of the first polar body, indicating
completion of meiosis I. However, some elements cannot be evaluated as easily, such as
cytoplasmic and molecular maturation. Cytoplasmic maturation involves the cessation of RNA
synthesis after storing up large amounts of RNA and redistribution of organelles, while molecular
maturation includes accumulation of necessary molecules for proper fertilization and early
embryo development (Sirard, Richard et al. 2006).
During its growth phase, the oocyte synthesizes and stores up mRNAs, which is a
necessary component of cytoplasmic maturation. These transcripts are essential for early embryo
development up to the maternal-to-embryonic transition (MET), at which time the embryo begins
clearing out maternal transcripts and activating its own genome for new transcription to take
place (Graf, Krebs et al. 2014, Lee, Bonneau et al. 2014). Increased abundance of maternal
transcripts has been associated with higher blastocyst rates (Lonergan, Rizos et al. 2003).
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Therefore, it is reasonable to consider that levels of these maternal transcripts may reflect oocyte
quality. However, because the maternal transcripts begin to degrade early in embryo
development, it is important to inspect the transcripts from the oocyte prior to it contributing to an
embryo.
Determining oocyte quality in a non-invasive manner would be ideal for increasing
blastocyst development. It would allow for selection of the highest-quality oocytes to be used for
ART. However, for such an assay to be make possible, the defining characteristics that make up a
good quality oocyte must first be understood.

A series of three experiments utilizing cytoplasmic biopsies of bovine oocytes
were completed to study the transcripts within the oocytes. Experiment 1 assessed the
impact of the biopsy on the developmental potential of the oocytes. Next, Experiment 2
examined the relationship between the transcripts of the biopsies and their corresponding
oocytes. Finally, Experiment 3 evaluated and compared transcript levels in biopsies from
oocytes that developed to the blastocyst stage and biopsies from oocytes that did not
reach the blastocyst stage following parthenogenetic activation. This experiment is a
technical step toward defining oocyte competence at a molecular level.
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MATERIALS AND METHODS

All chemical reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless
otherwise noted. These experiments were deemed to be exempt from the Institutional Animal
Care and Use Committee (IACUC) since no live animals were used at any point during these
studies; all tissue, rather, was donated after harvest from a local abattoir.

Oocyte Collection and In Vitro Maturation
Bovine oocytes were harvested and matured using thoroughly validated protocols utilized
and described previously (Cuthbert, Russell et al. 2019). Briefly, upon arrival, the ovaries were
washed in a saline solution and an 18-gauge needle was used to aspirate follicles 3-8 mm in size.
Following aspiration, the cumulus-oocyte complexes (COCs) were washed in PB1+ (phosphatebuffered saline with 3 mg/ml bovine serum albumin, 5.55 mM glucose, 0.32 mM sodium
pyruvate, and 1% penicillin/streptomycin), and those with compact cumulus cells were selected
for maturation. The COCs were then placed in maturation medium [TCM-199 (Gibco, Grand
Island, NY) with 100 U/ml penicillin/streptomycin, 0.5 µg/ml FSH, 5 µg/ml LH, and 10% fetal
bovine serum] and cultured for 22-24 h at 38.5ºC and 5% CO2 in humidified air (Keim 2019).
Details of the components of the PB1+ and the maturation medium are shown in Table 1.

Parthenogenetic Activation and In Vitro Culture
After maturing for 24 hours, the cumulus cells were removed from the COCs by pipetting
up and down in 0.6 mg/ml hyaluronidase from bovine testes in M199. Denuded oocytes were
held in PB1+ and visualized using a stereomicroscope to evaluate nuclear maturation. Only
oocytes that had a homogeneous cytoplasm and had successfully matured to metaphase II (MII),
indicated by the extrusion of the first polar body, were chosen for parthenogenetic activation. The
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MII oocytes were placed back into maturation medium in the incubator for 30 minutes to rest
before beginning the biopsy procedure or activation.
After the resting period, the MII oocytes were removed from the maturation medium, and
an ooplast biopsy equivalent to approximately 10% of the full cytoplasmic volume of the oocyte
was removed via micromanipulation. Control oocytes remained in culture and were not subjected
to any biopsy removal or micromanipulation procedures. After biopsy, oocytes were then
subjected to a parthenogenetic activation protocol. To begin the chemical activation, the oocytes
were placed in a solution containing 5 nM ionomycin diluted in HEPES-buffered synthetic
oviductal fluid (HSOF; 10 mM HEPES, 1.17 mM CaCl2, 0.49 mM MgCl2, 1.19 mM KH2PO4,
7.16 mM KCl, 107.7 mM NaCl, 2.0 mM NaHCO3, 5.3 mM sodium lactate, 0.02 mM sodium
pyruvate, 3 mg/ml bovine serum albumin (BSA), and 1% (v:v) penicillin/streptomycin (Denicol,
Block et al. 2014)) for 5 minutes and then washed thoroughly in PB1+. They were then
transferred to a culture dish containing drops of activation media, which was composed of 10
µg/ml cycloheximide and 2 mM 6-DMAP in synthetic oviductal fluid with amino acids [SOFaa;
99.7 mM NaCl, 8.03 mM KCl, 1.19 mM KH2PO4, 25 mM NaHCO3, 1.36 mM CaCl2, 0.39 mM
MgCl2, 0.4 mM Na Pyruvate, 0.2 mM Glutamine, 2.7 mM Myo-Inositol, 1.5 mM
Glucose, 0.0025 g/ml Gentamicin, 6 mM Na Lactate acid, MEM Non-Essential Amino Acids
4% (v:v), MEM Amino Acids 12% (v:v), and FBS 5% (v:v)] covered with mineral oil. The MII
oocytes were washed through several drops of the activation media and then placed in their final
drop to incubate for 4 h at 38.5ºC with 5% CO2. The components of the media used during
parthenogenetic activation are shown in Table 2.
Following the 4 h culture period, the presumptive parthenotes (also referred to as
activated oocytes or just embryos, for short) were washed through several droplets of SOFaa
before being transferred to a well of a four-well plate containing 400 µl of SOFaa covered in 400
µl of mineral oil in each of the wells. The first well served as an additional wash step before
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moving them into the second well on the plate, in which the well-of-well (WOW) culture system,
developed by Gábor Vajta (Vajta, Korosi et al. 2008), was applied to keep each individual
parthenote separate from the others during in vitro culture. The WOW system involves making
small indentations, using an aggregation needle (DN-09, Biological Laboratory Equipment
Maintenance and Service Ltd., Budapest, Hungary), on the bottom of a large well to allow
separation of parthenotes in culture while also maintaining a shared environment. The 4-well
plate was then placed in an incubator at 38.5 ºC, 5% CO2, and 5% O2 for in vitro culture (IVC).
The embryos were evaluated at 48 hours post-activation (hpa) for cleavage and on day 8 for
blastocyst development rates. Any embryo that had two or more cells was considered to be
cleaved, while those that lysed, still contained only a single cell, or contained significantly
fragmented cytoplasm were not.

Staining and Cell Counting
On day 8, parthenotes were placed in 400 µl of 10% (v:v) neutral buffered formalin
together. Next, the embryos were stained with 12.3 µg/ml Hoechst 33342 (Product # 62249;
Thermo Fisher Scientific; Waltham, MA, USA) in TL-Hepes, and they were moved to a dark
environment to incubate for 30 minutes. After fixing/staining, the embryos were washed through
the three additional wells of 400 µl PB1+. Each embryo was then transferred individually onto a
glass slide and then covered in a small amount of Fluoromount-G® (SouthernBiotech,
Birmingham, AL). A small dab of 1:1 petroleum jelly:paraffin wax was then placed on the
corners of the slide cover before placing it on top of the embryos. The embryos were then
inspected with a Zeiss AXIO Observer.Z1 Inverted Fluorescence Motorized Phase Contrast
Microscope and the number of nuclei counted and recorded for each embryo, regardless of
whether the embryo was a blastocyst.
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RNA Isolation and Reverse Transcription
All oocyte and biopsy samples were stored at -80ºC from the time of collection until
RNA isolation was performed. The Quick-RNA™ Microprep Kit (Zymo Research, Irvine, CA)
was used to isolate the RNA, following the manufacturer’s recommended protocol, with the
exception that the final elution of the RNA in DNase/RNase-Free Water was performed using 10
µl rather than their recommended 15 µl. The optional DNase I treatment was also excluded due to
the small sample size and because the cytoplasmic biopsy samples should not include any
genomic DNA. The RNA samples were immediately stored at -80ºC again until all samples were
isolated.
Once RNA was extracted from all samples, reverse transcription was completed using the
GoScript™ Reverse Transcription System (Promega, Madison, WI). For each sample, 8 µl of
RNA was mixed with 1 µl of oligo(dT) primers and 1 µl of random primers. This mixture was
then placed in a preheated thermocycler programmed to maintain a 70ºC for 5 minutes followed
by 4ºC for 5 minutes. While the samples ran in this program, a reaction mix was composed by
combining 4 µl of GoScript™ 5X Reaction Buffer, 4 µl MgCl2, and 1 µl PCR Nucleotide Mix per
sample. Once the samples in the thermocycler completed the 5 minutes at 4 ºC, 9 µl of the
reaction mix was added to each sample tube while the tubes remained on the block. Next, 1 µl of
GoScript™ Reverse Transcriptase was added to each sample except for negative control samples,
to which 1 µl of water was added instead, for a total of 20 µl per tube. The samples then were
subjected to a 25 ºC-annealing step in the thermocycler for 5 minutes, an extension period at 42ºC
for one hour, and finally, an enzyme inactivation step at 70ºC for 15 minutes. The samples were
then immediately removed from the block and stored at -20ºC until PCR was performed.
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Quantitative PCR
Quantitative PCR was performed using the 48.48 Dynamic Array ™ integrated fluidic
circuit (IFC) and 96.96. Dynamic Array ™ IFC on the BioMark system from Fluidigm (South
San Francisco, CA) for Experiments 2 and 3 respectively. The manufacturer-recommended
protocols for specific target amplification (STA), or preamplification, of cDNA (PN 100-5875
C1) and gene expression with the 48.48 and 96.96 IFCs using delta gene assays (PN 100-9791 B1
and PN 100-9792 B1) were used with some minor modifications noted below based on a less
recent protocol from Fluidigm.
All samples for both experiments were preamplified and treated with Exonuclease I.
First, all stock primer pairs at 100 µM each were diluted to 20 µM. Using the diluted primers, a
pooled STA Primer Mix was prepared by mixing 4 µl of each pair and adding nuclease-free water
until the total volume reached 400 µl. Next, 1.25 µl/reaction of the pooled primer mix was
combined with 2.5 µl/reaction of TaqMan™ PreAmp Master Mix (2X) (Applied Biosystems,
Waltham, MA.) A 96-well plate was then labelled as a sample plate and 3.75 µl of the solution
was distributed to each sample well. Next, 1.25 µl of each cDNA sample was added to each of the
wells. The sample plate was then placed in the thermocycler and the following protocol was used:
95ºC for 10 minutes, 14 cycles of 15 seconds at 95ºC followed by 4 minutes at 60ºC, and held at
4ºC until removed from the machine.
Next, the samples were treated with Exonuclease I. In a clean 1.5 mL tube, 1.4
µl/reaction of nuclease-free water was combined with 0.2 µl/reaction of Exonuclease I Reaction
Buffer and 0.4 µl/reaction of Exonuclease I. Then, 2 µl of the mix was added to each of the wells
containing preamplified samples. The sample plate was then placed in the thermocycler with the
thermal protocol including a digest step at 37ºC for 30 minutes, inactivation step at 85ºC for 15
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minutes, and a hold at 4ºC until the samples were removed. Finally, each sample of the plate was
diluted 5-fold by adding 18 µl of nuclease-free water.
For both the 48.48 and 96.96 IFCs, the following was mixed for each sample inlet: 2.5 µl
of TaqMan™ Gene Expression Master Mix (Applied Biosystems), 0.25 µl of 20X EvaGreen®
DNA Binding Dye (Biotium, Fremont, CA), 0.25 µl of 20X DNA Binding Dye Sample Loading
Reagent (Fluidigm), 0.75 µl nuclease-free water, and 1.25 µl of diluted cDNA samples that were
preamplified and treated with Exonuclease I. The mix was centrifuged and the IFC injected with
control line fluid and primed (using the MX and HX instruments) before loading 4.5 µl of the mix
into each sample inlet of the IFC.
Each assay inlet, for both sizes of IFCs, was then loaded with 4.5 µl of the following mix:
2.5 µl of 2X Assay Loading Reagent (Fluidigm), 2.25 µl of 20 µM combined forward and reverse
primers, and 0.25 µl of nuclease-free water. Each assay, for both IFCs in experiments 2 and 3,
was loaded twice for technical replication. The gene information used for each IFC is provided in
Tables 3 and 4.
Once all inlets were filled, the IFC was placed back in the MX or HX instrument, and the
load script was run. Next, dust was removed from the IFC using tape, the IFC was inserted into
the BioMark machine, and a new data collection run was started using the application type Gene
Expression, passive reference of ROX, and a single probe assay with the probe type being
EvaGreen.
The two sizes of IFCs require slightly different thermal protocols. The 48.48 requires a
hot start step (95ºC for 1 minute), a PCR cycle (40 cycles of the denaturing step at 96ºC for 5
seconds followed by the annealing step at 60ºC for 20 seconds), and a melting step in which the
temperature was help at 60ºC for an additional 3 seconds and then rose by 1ºC every 3 seconds
until the temperature reached 95ºC. The protocol for the 96.96 IFC was similar, but a thermal mix
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step is required at the beginning in which the temperature is held at 70ºC for 40 minutes and then
60ºC for 30 seconds. The hot start step is next, but rather than maintaining the 95ºC for 1 minute,
it is held for 10 minutes. The remainder of the protocol is identical to the 48.48 for the PCR cycle
and melting steps.

Experimental Design and Statistical Analysis
Experiment 1
In Experiment 1, oocytes were collected and matured in vitro as described above. Over a
period of six different days, 429 oocytes were parthenogenetically activated. On each day, there
were approximately 33 oocytes in the biopsy group (the 10% biopsies were discarded) and 33 in
the control group (no biopsy was taken from the oocyte prior to chemical activation). On day 2 of
in vitro culture, cleavage rates were assessed, and on day 8, blastocyst development rates were
determined and all parthenotes, regardless of developmental stage, were stained and the cells
counted for control and biopsy groups.
Statistical analysis of Experiment 1 included comparing the cell counts, for all embryos,
successful embryos, and failed embryos and the blastocyst rates using Welch’s t-test. The average
rates and counts for each group were also calculated along with their standard errors of the mean
(SEM) and represented using bar graphs.
Experiment 2
Oocytes were collected and matured using the protocol described previously. Biopsies
were taken from 10 MII oocytes on 4 different days, for a total of 40 oocyte-biopsy pairs. Each
oocyte or biopsy was placed separately into 1 µl DPBS in individual 0.2 ml RNase/DNase-free
tubes and stored at -80ºC for later use. Once all 40 oocyte-biopsy pairs were collected and stored,
five pairs from each collection day were selected for RNA isolation. RNA was extracted from
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three additional pairs, each from a separate collection day. The RNA from the three oocytes was
combined, and the RNA from the three biopsies was combined to be used as negative controls
during reverse transcription. Next, reverse transcription was completed on all 20 pairs followed
by quantitative PCR using Fluidigm’s 48.48 Dynamic Array ™ IFC as described above.
The relationship between Ct values for each gene/primer pair from oocytes and their
biopsies were analyzed using the regression model for each pair. A Ct value is inversely related to
the amount of transcript in a sample because it denotes the number of PCR cycles a sample
underwent before reaching a particular detection threshold. The significance for each regression
was then examined, and the R-squared values of all the pairs with results from the PCR were
averaged.
Experiment 3
Oocytes were collected from the slaughterhouse and matured in vitro. Of those that
matured successfully, 40 were selected to be biopsied. The biopsies were placed in 0.2 ml tubes
containing 1 µl of DPBS, numbered, and stored at -80ºC for later use. After each oocyte was
biopsied, it was then placed into an individual droplet of holding medium covered in mineral oil
in order so that the identity of each oocyte was known. An additional 40 matured oocytes were
selected for the control group which would not be biopsied.
All oocytes were then parthenogenetically activated. However, the biopsy group required
a slight modification to the protocol in order to keep all of the oocytes separate throughout the
activation process for identification purposes. To do this, each oocyte was assigned its own
droplet for each step and wash, rather than moving the oocytes through each drop as a group.
Once again, oocytes were cultured using the Well-of-the-Well (WOW) system during
development. At 48 hpa, the embryos were examined for cleavage rates, and the stage of each
embryo at that time was recorded. They were then checked on day 8 for blastocyst rates, and the
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identity of the blastocysts was noted. This activation protocol was repeated on six different days,
for a total of 239 biopsied oocytes and 240 control oocytes.
Next, 45 of the embryos that developed to the blastocyst stage and 45 that failed to reach
the blastocyst stage were selected as the reference populations for the study. The total number of
blastocysts out of all six replicates was 48, so the oocyte biopsies corresponding to the first 45
embryos were selected to be used. However, the 45 failed biopsies selected included all embryos
that were at the 1-cell and 2-cell stage at 48 hpa (n = 27). The remaining samples selected were
split between those that were at the 4-cell (n = 10) and those at the 8-cell (n = 8) stages at 48 hpa
and approximately equal numbers chosen from each of the 6 replicate days. Using the protocol
described above, RNA isolation was then completed on the 90 frozen oocyte biopsies
corresponding to the selected embryos, 2 additional biopsies to serve as negative controls (no
reverse transcription), and a group of five oocytes together to serve as a positive control.
The GoScript™ Reverse Transcription System was again used to convert RNA samples to cDNA,
but the reaction volumes were halved, resulting in a total reaction volume of 10 µl rather than the
20 µl volume used during Experiment 2. One RNA sample from an oocyte biopsy in the
blastocyst group and one from an oocyte biopsy in the failed group were used as negative controls
with no GoScript™ Reverse Transcriptase added.
Once all samples had been converted to cDNA, PCR was performed using Fluidigm’s
96.96 Dynamic Array ™ IFC. The collection of Ct values obtained from qPCR without any
normalization will be referred to as raw Ct data from here on to help distinguish it from delta Ct
data, which was the raw Ct value for each sample normalized to the average raw Ct values for
each of four “housekeeping” genes: ACTB, EIF4A1, YWHAZ, and ZP2. Any reactions with no
amplification were considered missing values. The raw Ct and delta Ct data resulting from the
qPCR was analyzed in the statistical program R (Ihaka and Gentleman 1996), using the linear

37
models for microarray data (LIMMA), which allows for pooling of information across genes for a
more accurate variance estimate and accounts for group and day effects (Ritchie, Phipson et al.
2015.
The raw Ct data and delta Ct data were also assessed using the ClustVis program
(available at https://biit.cs.ut.ee/clustvis/) an unsupervised bi-directional hierarchical clustering
heat map in which reactions were organized by similarity in expression between samples for each
of the 48 genes. The Manhattan clustering approach was applied with the complete linkage
method and without row centering or variance scaling.

TABLE 1.
Pre-Activation Media.

Media

PB1+

Maturation

Stripping COCs

Reagent Name
PBS (containing Ca2+ and Mg2+)
3 mg/ml Bovine Serum Albumin (BSA)
5.55 mM Glucose
0.32 mM Sodium Pyruvate
1% Penicillin/Streptomycin
Medium 199
100 U/ml Penicillin/Streptomycin
0.5 µg/ml FSH
5 µg/ml LH
10% Fetal Bovine Serum
0.6 mg/ml Hyaluronidase from Bovine Testes
M199

Source

Product #

Sigma-Aldrich
Sigma-Aldrich

G6152
P4562

Sigma-Aldrich

M4530

Sigma-Aldrich
Sigma-Aldrich

H3506
M4530

Note. Media used prior to oocyte activation (washing, maturing, and stripping oocytes), along with the
required reagents of the media. The sources and product numbers of certain, specific reagents are also
listed.
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TABLE 2.
Oocyte Activation Media.

Media

HSOF

SOFaa

Activation

Reagent Name
10 mM HEPES
1.17 mM Calcium Chloride Dihydrate (CaCl2)
0.49 mM Magnesium Chloride Hexahydrate
(MgCl2)
1.19 mM Potassium Phosphate Monobasic
(KH2PO4)
7.16 mM Potassium Chloride (KCl)
107.7 mM Sodium Chloride (NaCl)
2.0 mM Sodium Bicarbonate (NaHCO3)
5.3 mM Sodium Lactate
0.02 mM Sodium Pyruvate
3 mg/ml Bovine Serum Albumin (BSA)
1% (v:v) penicillin/streptomycin
99.7 mM Sodium Chloride (NaCl)
8.03 mM Potassium Chloride
1.19 mM Potassium Phosphate Monobasic
(KH2PO4)
25 mM Sodium Bicarbonate (NaHCO3)
1.36 mM Calcium Chloride Dihydrate (CaCl2)
0.39 mM Magnesium Chloride Hexahydrate
(MgCl2)
0.4 mM Sodium Pyruvate
0.2 mM Glutamine
2.7 mM Myo-Inositol
1.5 mM Glucose
0.0025 g/ml Gentamicin
6 mM Sodium Lactate
4% (v:v) NEAA
12% (v:v) EAA
5% (v:v) FBS
10 µg/ml Cycloheximide
2 mM 6-DMAP
SOFaa

Source
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich

Product #
H6147
C7902
M2393

Sigma-Aldrich

P5655

Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich

P5405
S5886
S5761
L7900
P4562

Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich

S5886
P5405
P5655

Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich

S5761
C7902
M2393

Sigma-Aldrich
Gibco
Sigma-Aldrich
Sigma-Aldrich

P4562
11130
17508
G6152

Sigma-Aldrich
Gibco

L7900
11140

Sigma-Aldrich
Sigma-Aldrich

C7698
D2629

Note. Media used during the oocyte activation process, along with the required reagents of the media. The
sources and product numbers of certain, specific reagents are also listed.
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TABLE 3.
Experiment 2 Primer Sequences.
GENE
BAX
BCL2
FAS
MDM2
DNMT3B
EZH2
HDAC1
SUV39H1
GAPDH
TAF11
YWHAZ
ACACA
FABP3
IGF2R
SLC2A1
BMP15
GDF9
NLRP5
YBX2
ZAR1
CNOT6L
DDX6
DND1
TUT7

ACCESSION
NM_173894.1
NM_001166486.1
NM_174662.N
NM_001099107.1
NM_181813.2
NM_001193024.1
NM_001037444.2
NM_001046264.2
NM_001034034.2
NM_001034276.1
NM_174814.2
NM_174224.N
NM_174313.N
NM_174352.N
NM_174602.N
NM_001031752.N
NM_174681.N
NM_001007814.N
NM_001098126.N
NM_001076203.N
NM_001191523.2
NM_001143867.3
NM_001193145.1
NM_001205752.2

FUNCTION
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Epigenetic
Epigenetic
Epigenetic
Epigenetic
Housekeeping
Housekeeping
Housekeeping
Metabolism
Metabolism
Metabolism
Metabolism
Oocyte
Oocyte
Oocyte
Oocyte
Oocyte
RNA Processing
RNA Processing
RNA Processing
RNA Processing

EXP
2,3
2,3
2
2,3
2,3
2
2,3
2,3
2
2,3
2,3
2,3
2,3
2,3
2,3
2,3
2,3
2,3
2,3
2,3
2,3
2
2
2,3

5'- F PRIMER SEQUENCE -3'
CGGGTTGTCGCCCTTTTCTA
ATGTGTGTGGAGAGCGTCAA
GAAATGCACACCAACGAGCAA
CAGATTCCAGCTTCGGAACAA
GCCAAAGCTCTTCCGAGAAA
GAGCCATCCAGACTGGTGAA
ATGTCCGAGTACAGCAAGCA
TCGAGTACCTGTGCGATTACA
GGGTCTTCACTACCATGGAGAA
AGAGAAGAAGCAGAAAGTGGATGAA
AACAGCAGATGGCTCGAGAA
GCTAACTCAACTCAGCAAGACC
ACCACAGCAGATGACAGGAA
GGCAGATTCCACTCAAGTCA
GTGGGCATGTGCTTCCAGTA
TGGACACCCTAGGGAAAACC
AACACTGTTCGGCTCTTCAC
GACCAAGGTCCAAGCATGAAA
GTCCTGGGCACTGTCAAA
ACCCTTACCGAGTGGAGGATA
TCTGAGCAGGAGAGAAAGCA
ACCTGGTGATGACTGGAAAA
GCACAGATAGCACTGCTCAA
CAGCCATTGATCCCAGAGTGAA

5'- R PRIMER SEQUENCE -3'
GCCCATGATGGTCCTGATCAA
GGTTCAGGTACTCGGTCATCC
AGGATCAGGAGGGCCCATAAA
CTGTGCACCAACAGACTTCA
GGGTGGAGGTACTGCTGTTA
TTCGATGCCCACGTACTTCA
CAGAACTCAAACAGGCCATCAAA
GGGTACCCACGCCATTTTAC
GTTCACGCCCATCACAAACA
GGTTCAGCTGCTCCTCAGAA
GAAGCGTTGGGGATCAAGAAC
GGATGGCAAATGGGAAGCAA
GACAAGTTTGCCGCCATCC
AGATCAAGGTGAGGTCTCCA
GAACCAGGAGCACGGTGAA
GAGGAAAGTCCAGGGTCTGTA
ACAGCAGATCCACTGATGGAA
TCACGTGGATCCTGTAGTCC
AAAACATCCTCCTTGGTGTCA
TCCACATGGCGAAGTTTCAC
CACTGTATGCTTCTGCACCAA
TTCCTTTTGTGGAGGTCACA
ACAGCCACCTGTTCTCCA
GCCTCTAGAAGCATCGCCAATA

Note. List of genes that were studied in Experiment 2 (EXP 2), many of which were also included in Experiment 3 (EXP 3), along with the functional categories
and forward (F) and reverse (R) primer sequences.
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Table 4.
Experiment 3 Primer Sequences.
GENE
BCL2L1
BID
CASP3
CASP8
CASP9
P53
DNMT1
DNMT3A
EHMT2
HDAC2
HSPA1A
ACTB
EIF4A1
ACSL3
G6PD
IGF1
PPARG
CCNB1
CDK2
KITLG
ZP2
KLF4
LIN28A
POU5F1
SOX2
CELF1
CPEB2
VIRMA
YTHDF2

ACCESSION
NM_001077486.2
NM_001075446.N
NM_001077840.1
NM_001045970.N
NM_001205504.2
NM_174201.2
NM_182651.2
NM_001206502.1
NM_001206263.1
NM_001075146.1
NM_203322.N
NM_173979.3
NM_001034228.1
NM_001205468.N
NM_001244135.N
NM_001077828.N
NM_181024.N
NM_001045872.N
NM_001014934.N
NM_174375.N
NM_173973.N
NM_001105385.1
NM_001193057.1
NM_174580.2
NM_001105463.2
NM_001101212.1
XM_024993638.1
NM_001205426.1
NM_001076253.1

FUNCTION
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Epigenetic
Epigenetic
Epigenetic
Epigenetic
Housekeeping
Housekeeping
Housekeeping
Metabolism
Metabolism
Metabolism
Metabolism
Oocyte
Oocyte
Oocyte
Oocyte
Pluripotency
Pluripotency
Pluripotency
Pluripotency
RNA Processing
RNA Processing
RNA Processing
RNA Processing

5’- F PRIMER SEQUENCE -3’
ATGTGTGTGGAGAGCGTCAA
ACGGTGACCTTCATCAACCA
AGTCTGACTGGAAAACCCAAAC
TGAGCCAGGAGATTGCCAAA
TCACTGTGAGGACCTTCAGAC
CCCATCCTCACCATCATCACA
AGAGACGTCGAGTTACATCCA
CCATGTACCGCAAGGCTATCTA
GACGTCCACCATGAACATTGAC
AAGGAGGCGGCAAGAAGAAA
CTGATCAAGCGCAACTCCA
GCCAACCGTGAGAAGATGAC
CAGAAGCTCAACAGCAACAC
TGGCGGAAAGGATTCCAGAA
GTCTGGTGGCCATGGAGAA
GAGTTGGTGGATGCTCTCCA
CTTGCTGTGGGGATGTCTCA
TTTAGTCTGGGTCGCCCTCTA
TTTTGGGGTCCCTGTTCGTAC
CCAGCTCCCTTAGGAATGACA
AGAACCAGAAGATGAGCATCCA
GCGGCAAAACCTACACGAA
GCGGCCCAAAGGGAAGAATA
AGAAGCTGGAGCCGAACC
CCCAAGAGAACCCTAAGATGCA
AAGCTCAGAACGCTCTTCACA
AGCCCAACCATCAAGGACAA
GCCACAGCCAAGTGTGAAAA
GAGAAACGCCAAGAGGAAGAA

5’- R PRIMER SEQUENCE -3’
GGTTCAGGTACTCGGTCATCC
CCGAGTGGTCACTCAGTCC
AGCACCACTGTCTGTCTCAA
TGGTCCTCTTCTCCATCTCCA
GCCCGGCATCTGTTTGTAAA
GCACAAACACGCACCTCAA
GTGTTCCTGGTCTTACTCTTCC
GCTGTCATGGCACATTGGAA
CTGGAGCAGTCATCCACACA
TGGGATGACCCTGTCCGTAATA
TTGTCCGAGTAGGTGGTGAA
CCTGGATGGCCACGTACA
CTTCTTGGTCACCTCAAGCA
AGACAGACAAGCTCAGCACTTA
CTGCACCTCTGAGATACACTTCA
GACTGCTCGAGCCATACCC
ATCTCCGCTAACAGCTTCTCC
GGCCAGAGTATGTAGCTCAACA
TGCAGCCCAGAAGGATTTCC
TGCCCATTGTAGGCTGGAA
AGCTTCAGAGGCACCATGTA
CCATCCCAGTCACAGTGGTAA
CACTCCTTGGCATGATGGTCTA
CTGCTTTAGGAGCTTGGCAAA
CCGTCTCGGACAAAAGTTTCC
GTCGGCAGGCTTCATCTGTATA
AGGCTGAGAACCATCCATCAC
GGTCTTGGAGGGCTTCCATTAA
TCTGTGCAGAACTGCCTCTTA

Note. Genes for Experiment 3 (in addition to those already noted from Table 3) along with their functions and forward (F) and reverse (R) primer sequences.
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RESULTS

Experiment 1
Experiment 1 data was analyzed by comparing average blastocyst rates and cell counts of
embryos between the control group and the biopsy group. The average blastocyst rates were
27.9±5.3% and 26.7±3.7% for the control and biopsy groups respectively, which are not
significantly different from each other (P > 0.05; Figure 1A). The average cell counts of the
blastocysts for each group also did not differ significantly. Blastocysts in the control group had an
average of 78.8±4.9 cells while the biopsy group had an average of 71.0±4.6 cells per blastocyst
(Figure 1B). Similarly, the average cell counts of failed embryos in each group were compared.
The averages were 7.7±1.8 and 7.0±1.4 cells per failed embryo for the control and biopsy groups
respectively. The difference between the groups for the failed embryos was statistically
significant (P < 0.05; Figure 1C). However, when the total average embryo cell counts for each
group, including failed embryos and blastocysts together, the difference was not significant with
the average count of the control group at 33.7±3.5 cells and biopsy group at 27.6±3.0 cells
(Figure 1D). Examples of the observed embryo groups and stained blastocysts are shown in
Figure 2.
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FIGURE 1.
Comparison of Parthenote Cell Counts and Blastocyst Rates.

Note. A) Comparison of the averages of the blastocyst rates across the six replicates between the
control and biopsy group. B) Comparison of the average cell counts for all blastocysts over the
six replicates for the control group and the biopsy group. C) Comparison of the average cell count
for all failed embryos within the control and biopsy groups. D) Comparison of the cell counts for
all embryos, both blastocysts and failed embryos, between the control and biopsy groups. Control
(C) groups are in blue, and biopsy (B) groups are brown. * = P <0.05; ns = P>0.05
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FIGURE 2.
Control and Biopsy Group Embryo Images.

Note. A) Day 8 embryos from a control group. B) A control group blastocyst embryo stained with
Hoechst for cell counting. C) Day 8 embryos from a biopsied oocyte group. D) A biopsy group
embryo stained with Hoechst for cell counting. Images A and C were taken under a brightfield
microscope, and images B and D were taken under a Zeiss AXIO Observer.Z1 Inverted
Fluorescence Motorized Phase Contrast Microscope.

Experiment 2
In order to understand the relationship between the cytoplasmic biopsies and the
remaining oocyte cytoplasm, the Ct values of each biopsy, resulting from qPCR of 24 genes, were
plotted against the Ct values of the corresponding oocyte for those same genes. Each oocytebiopsy pair was analyzed individually, and the linear regression model was applied to each pair.

44
Pairs 1, 4, 16, 17, and 18 were not analyzed due to less than 30% of the reactions demonstrating
successful amplification for either the oocyte or biopsy samples in the pair. Using the linear
regression model, R2 values were obtained for all other pairs (see Figure 3). The lowest R2 value
of 0.5529 was observed with pair 10 while the highest value was 0.9532 with pair 20. The
average R2 value for all 17 pairs was 0.8339, and all calculated R2 values suggested significant
positive correlation between samples (all p-values less than 0.001; data not shown).

FIGURE 3.
Linear Regression Models and R2 Values.

Note. A) Linear regression model fit to the Ct data for oocyte-biopsy pair 20, which had the highest R2
value out of the 17 pairs. B) A linear regression model fit to the Ct data for pair 7, which had an R 2 value
similar to the mean of all the pairs. C) A linear regression model fit to the Ct data for pair 10, which had the
lowest R2 values of all the pairs. The R2 value in each of the panels (A, B, and C) is displayed on the right
above the x-axis. D) The number of pairs that fall within each range of R2 values.
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Experiment 3
Differences in transcript levels between the successful (S) and failed (F) oocyte groups
were statistically significant for only three of the genes within the raw Ct data: BID (P = 0.015),
CPEB2 (P = 0.011), and LIN28A (P = 0.041). However, once the false discovery rate (FDR)
correction accounting for multiple tests was applied, the differences were no longer statistically
significant for any of the 48 genes at a significance level of 0.05 (See Figure 5A and Table 5).
When the delta Ct values were analyzed using the same LIMMA package, CPEB2 (P =
0.011) and HSPA1A (P = 0.017) did have statistically significant differences in transcript levels
between the success and failure groups, but, again, only before the p-value was adjusted based on
the false discovery rate (Figure 5B and Table 6). Once all p-values were adjusted, there were no
significant differences in normalized expression between the groups for any of the genes.
The unsupervised bi-directional hierarchical clustering heat maps of the raw Ct data (see
Figure 6) and delta Ct data (see Figure 7) revealed no obvious segregation of sample types
(blastocysts/successful oocyte biopsy samples and failed oocyte biopsy samples) based on the Ct
or delta Ct values for any of the 48 genes.
There was a total of 48 blastocysts out of 239 total parthenogenetically activated oocytes,
resulting in a total blastocyst rate of 20.1%. Figure 4 displays some of the blastocysts observed
during Experiment 3.
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FIGURE 4.
Experiment 3 Blastocysts.

Note. A) A day 8 blastocyst that has expanded but not yet hatched from the zona pellucida. B) A day 8
blastocyst that is in the process of hatching. C) A completely hatched day 8 embryo.
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FIGURE 5.
Comparison of Raw Ct and Delta Ct Trends.

Note. A) Comparison of the trends in raw Ct values between the three genes that were differentially
expressed between the successful and failed oocyte groups prior to FDR correction of the p-values: BID,
CPEB2, and LIN28A. B) Comparison of the trends in the delta Ct (dCt) values of the two genes that were
differentially expressed between the successful and failed oocyte groups prior to FDR correction of the pvalues: CPEB2 and HSPA1A. For both figures, successful oocyte groups are denoted by an (S), and failed
oocyte groups are denoted by an (F) on the x-axis. The whiskers represent the minimum and maximum
values of the data for the gene. The box extends to the 25 th and 75th percentiles with the inner line at the
median.
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TABLE 5.
Raw Ct Results.
GENE
BID
BAX
BCL2
BCL2L1
CASP3
CASP8
CASP9
MDM2
P53
DNMT1
DNMT3A
DNMT3B
EHMT2
HDAC1
HDAC2
SUV39H1
ACTB
EIF4A1
HSPA1A
TAF11
YWHAZ
ACACA
ACSL3
FABP3
G6PD
IGF1
IGF2R
PPARG
SLC2A1
BMP15
CCNB1
CDK2
GDF9
KITLG
NLRP5
YBX2
ZAR1
ZP2
KLF4
LIN28A
POU5F1
SOX2
CELF1
CNOT6L
CPEB2
TUT7
VIRMA
YTHDF2

FUNCTION
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Epigenetic
Epigenetic
Epigenetic
Epigenetic
Epigenetic
Epigenetic
Epigenetic
Housekeeping
Housekeeping
Housekeeping
Housekeeping
Housekeeping
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Oocyte
Oocyte
Oocyte
Oocyte
Oocyte
Oocyte
Oocyte
Oocyte
Oocyte
Pluripotency
Pluripotency
Pluripotency
Pluripotency
RNA Processing
RNA Processing
RNA Processing
RNA Processing
RNA Processing
RNA Processing

MEAN S
21.10
19.92
20.12
20.89
20.16
N/A
20.55
19.87
21.12
16.50
N/A
18.68
19.90
21.08
20.18
20.06
18.45
17.46
17.51
21.14
18.69
21.30
19.18
18.62
19.48
27.08
20.84
18.81
21.55
15.88
16.50
20.75
18.31
20.79
17.31
16.55
17.51
16.38
19.65
18.68
20.29
18.96
18.64
18.09
20.68
19.33
19.45
22.22

MEAN F
20.27
20.03
19.96
20.50
19.86
20.27
20.98
19.57
20.78
16.73
N/A
18.60
19.76
20.92
20.51
19.84
18.46
17.36
16.92
21.54
18.82
21.41
19.18
18.26
19.37
27.10
20.27
18.55
21.95
16.15
16.67
20.11
17.83
20.36
17.20
16.83
17.44
16.22
19.49
18.05
19.95
18.74
18.35
17.72
21.29
19.20
19.17
22.16

P-VALUE
0.015
0.633
0.687
0.242
0.461
N/A
0.776
0.231
0.131
0.339
N/A
0.763
0.691
0.386
0.616
0.371
0.984
0.909
0.101
0.439
0.672
0.753
0.913
0.272
0.907
0.098
0.109
0.326
0.670
0.506
0.628
0.161
0.310
0.444
0.801
0.424
0.791
0.842
0.326
0.041
0.253
0.386
0.455
0.269
0.011
0.766
0.281
0.794

FDR P-VALUE
0.343
0.898
0.898
0.816
0.816
N/A
0.898
0.816
0.816
0.816
N/A
0.898
0.898
0.816
0.898
0.816
0.984
0.934
0.816
0.816
0.898
0.898
0.934
0.816
0.934
0.816
0.816
0.816
0.898
0.862
0.898
0.816
0.816
0.816
0.898
0.816
0.898
0.922
0.816
0.626
0.816
0.816
0.816
0.816
0.343
0.898
0.816
0.898

Note. List of genes that were analyzed using LIMMA along with the functional category, mean Ct value for the
successful embryonic development oocyte group (Mean S), mean Ct value for the failed embryonic development
oocyte group (Mean F), p-value, and false-discovery rate (FDR) corrected p-value for each gene. N/A = no
amplification in any of the experimental samples.
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Table 6.
Delta Ct Results.
GENE
BAX
BCL2
BCL2L1
BID
CASP3
CASP8
CASP9
MDM2
P53
DNMT1
DNMT3A
DNMT3B
EHMT2
HDAC1
HDAC2
SUV39H1
ACTB
EIF4A1
HSPA1A
TAF11
YWHAZ
ACACA
ACSL3
FABP3
G6PD
IGF1
IGF2R
PPARG
SLC2A1
BMP15
CCNB1
CDK2
GDF9
KITLG
NLRP5
YBX2
ZAR1
ZP2
KLF4
LIN28A
POU5F1
SOX2
CELF1
CNOT6L
CPEB2
TUT7
VIRMA
YTHDF2

FUNCTION
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Apoptosis
Epigenetic
Epigenetic
Epigenetic
Epigenetic
Epigenetic
Epigenetic
Epigenetic
Housekeeping
Housekeeping
Housekeeping
Housekeeping
Housekeeping
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Oocyte
Oocyte
Oocyte
Oocyte
Oocyte
Oocyte
Oocyte
Oocyte
Oocyte
Pluripotency
Pluripotency
Pluripotency
Pluripotency
RNA Processing
RNA Processing
RNA Processing
RNA Processing
RNA Processing
RNA Processing

MEAN S
2.371
2.633
3.309
3.582
2.814
N/A
4.012
2.282
4.161
-1.198
N/A
0.905
2.214
3.958
2.779
2.982
0.677
-0.279
-0.236
3.843
0.987
4.173
1.518
0.968
2.650
10.429
3.377
1.221
4.548
-1.818
-1.241
3.401
0.655
3.611
-0.390
-1.190
-0.147
-1.361
2.180
0.978
2.678
1.255
1.063
0.364
3.808
2.382
1.746
5.289

MEAN F
2.942
2.945
3.099
3.230
2.816
3.331
4.464
2.257
4.234
-0.826
N/A
0.956
2.284
3.489
3.773
2.970
0.843
-0.420
-0.773
4.189
1.080
4.403
1.806
0.811
2.553
9.248
3.202
1.090
5.151
-1.543
-0.959
2.919
0.226
3.533
-0.445
-0.868
-0.062
-1.378
2.412
0.517
2.232
1.252
1.055
0.335
4.770
2.343
1.769
5.742

P-VALUE
0.165
0.437
0.522
0.535
0.674
N/A
0.785
0.793
0.555
0.126
N/A
0.961
0.833
0.068
0.080
0.881
0.558
0.350
0.017
0.432
0.673
0.871
0.421
0.500
0.845
0.080
0.770
0.631
0.323
0.352
0.262
0.169
0.141
0.830
0.849
0.235
0.829
0.976
0.529
0.088
0.244
0.826
0.991
0.925
0.011
0.802
0.968
0.315

FDR P-VALUE
0.778
0.988
0.988
0.988
0.989
N/A
0.989
0.989
0.988
0.778
N/A
0.991
0.989
0.676
0.676
0.989
0.988
0.954
0.381
0.988
0.989
0.989
0.988
0.988
0.989
0.676
0.989
0.989
0.954
0.954
0.926
0.778
0.778
0.989
0.989
0.926
0.989
0.991
0.988
0.676
0.926
0.989
0.991
0.991
0.381
0.989
0.991
0.954

Note. List of genes that were analyzed using LIMMA along with the functional category, p-value, falsediscovery rate (FDR) corrected p-value, mean delta Ct value for the successful embryonic development oocyte
group (Mean S), and mean delta Ct value for the failed embryonic development oocyte group (Mean F) for each
gene. In the case of no amplification, the missing values are shown as N/A.
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FIGURE 6.
Unsupervised Bi-directional Hierarchical Clustering Heat Map of Raw Ct Data.

Note. Unsupervised bi-directional hierarchical clustering heat map of the raw Ct data organized by
similarities in expression between samples for each gene. The Manhattan clustering approach was applied
along with the complete linkage method and no row centering or variance scaling. Lighter colors represent
higher Ct values (lower expression), while darker oranges and reds represent lower Ct values (higher
expression). White boxes represent dropout reactions in which no amplification occurred during qPCR.
Biopsy samples were labelled as Blast (blastocyst or successful development group) or Fail (failed to
develop group) followed by the sample number and the day after the underscore.
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FIGURE 7.
Unsupervised Bi-directional Hierarchical Clustering Heat Map of Delta Ct Data.

Note. Unsupervised bi-directional hierarchical clustering heat map of the delta Ct data organized by
similarities in expression between samples for each gene. The Manhattan clustering approach was applied
along with the complete linkage method and no row centering or variance scaling. Orange colors represent
higher delta Ct values (lower relative expression), while darker purples represent lower delta Ct values
(higher relative expression). White boxes represent dropout reactions in which no amplification occurred
during qPCR or no difference in Ct values between the gene and the housekeeping genes. Biopsy samples
were labelled as Blast (blastocyst or successful development group) or Fail (failed to develop group)
followed by the sample replicate number and the day after the underscore.
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DISCUSSION

The purpose of Experiment 1 of this study was to determine if removal of a 10%
cytoplasmic biopsy from an oocyte affects embryo development to the blastocyst stage. A control
group and a biopsied group of bovine oocytes was chemically parthenogenetically activated and
then cultured in vitro for eight days. When the average blastocyst rates, average blastocyst cell
counts, and average overall embryo cell counts were compared between the control and biopsy
groups, there were no significant differences. However, when the average failed embryo cell
count was compared between the biopsy and control group, the difference was statistically
significant. This is likely due to the large portion of failed embryos, in both groups, that could not
be counted accurately because of inadequate fluorescence and were counted as 1-cell embryos.
All embryos, regardless of developmental progress, were not stained until day eight. Therefore,
embryos that arrested during the eight-day culture period may have been degenerating for several
days prior to being stained. This issue led to less accurate average counts for the failed embryos
and would explain the large variation seen within the groups.
Overall, the data from this study supports that removing 10% of the oocyte cytoplast does
not impact embryo development of parthenotes to the blastocyst stage based on the insignificant
differences in cell counts for the blastocysts and all embryos combined, as well as the blastocyst
rates, between the biopsy and control groups. Another study (Biase, Everts et al. 2014), also
compared blastocyst development rates between bovine oocytes that had been biopsied and those
that had not. Similarly, they did not find evidence supporting any significant reduction in
developmental competence following a cytoplasmic biopsy. However, there is some evidence in
other contexts, using the same micromanipulation concepts, that suggest otherwise. A recent
study has shown that a new technique of performing intracytoplasmic sperm injection (ICSI), that
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breaks the oocyte membrane without aspirating some of the cytoplasm into the micropipette, has
much higher survival and fertilization rates (Hiraoka, Isuge et al. 2021). The results could
indicate that the act of aspiration is detrimental to many of the oocytes; however, ICSI is different
in that the aspirated cytoplasm is deposited back into the oocyte rather than being removed. More
studies around this new ICSI technique in the coming years may reveal more definitive answers.
Additionally, in cloning, micromanipulation technology is often used to remove the nucleus of
the recipient egg, which can include removing some of the cytoplasm with it (Ross and Feltrin
2014). If more than 10% is removed during this process, it can negatively impact developmental
ability of the embryos (Min, Park et al. 2018). Perhaps a 10% cytoplasmic biopsy is less
detrimental to oocytes undergoing parthenogenetic activation than any other form of
manipulation, but more research would be necessary to confirm such a claim. However, our data
supports that a 10% cytoplasmic biopsy does not significantly impact the developmental potential
of an oocyte.
The goal of Experiment 2 was to understand the relationship between the 10%
cytoplasmic biopsies and their corresponding oocytes and determine if the biopsy size would
result in a representative sample of the remaining oocyte transcripts. Quantitative PCR was
performed on the oocytes and their biopsies, using 24 genes from six different functional
categories run in duplicate. The Ct values of each biopsy was plotted against the Ct values of its
oocyte. Using linear regression models, R-squared values were acquired for each pair. In general,
the R-squared values were high, with the average being 0.8339, indicating a high positive
correlation between the Ct values. These results suggest that the biopsies are representative of the
remaining oocyte regarding the transcripts.
A biopsy of the cytoplasm will never be entirely representative of all the transcripts
within an oocyte because it is a sub-sample. Transcripts of low abundance are even less likely to
be included in the biopsy, especially if distribution of the transcript is not uniform within the
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cytoplasm. In fact, such a technique of sampling an oocyte in a non-mammalian model system,
with a known mechanism of RNA localization within the oocyte, would likely not allow for a
representative sample. The Balbiani body is largely responsible for the localization, as it
transports materials like mitochondria and RNA, and was thought to be absent in mammals until
recently (Kloc and Etkin 2005, Oh and Houston 2017). However, the Balbiani body appears to
disperse evenly in mammals (Oh and Houston 2017), which may suggest a different mechanism
for distribution of materials in the mammalian oocyte. Jansova et al. (2018) recognized the lack
of knowledge in this area and studied the localization of certain RNAs within the mouse and
human oocyte. The study focused mainly on differences in abundance between the nucleus and
the cytoplasm. The fluorescence images resulting from the study seem to show that the RNAs
were evenly distributed throughout the compartment of the cell that they occupied, in most cases.
Only a few RNAs showed any sign of localization, and those that did, appeared to be symmetrical
around the nucleus or near the periphery of the cytoplasm (Jansova, Tetkova et al. 2018). Still,
research on mammalian RNA localization in the oocyte is lacking, and studies focusing on
distribution primarily in the cytoplasm would be useful in understanding how representative a
biopsy sample may be. Nevertheless, our study indicates that a 10% cytoplasmic biopsy is
representative of the remaining oocyte concerning the mRNA transcripts.
The purpose of Experiment 3 was to identify any differential expression patterns that may
exist between the oocyte biopsies corresponding to embryos with successful development to the
blastocyst stage and biopsies from embryos that failed to develop to the blastocyst stage.
Identification of the different expression patterns could potentially reveal characteristics that
determine the quality of an oocyte, and consequently, its developmental potential. The qPCR
results of the cytoplasmic biopsies were compared between the successful and failed development
groups. Typically, delta-delta Ct data is reported and used for analysis because it normalizes the
data to both a reference sample and housekeeping genes. However, because the purpose of this
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study is to detect changes in transcript levels between such small portions of the oocyte,
normalization to housekeeping genes, or to both housekeeping genes and a reference sample
(delta-delta Ct data), may ultimately reduce any evidence of differential expression. Therefore,
we focused our analysis on the raw Ct and delta Ct results because they are less manipulated
forms of data. There is no way to be certain of the degree to which the normalization controls for
oocyte or biopsy size or hinders the true differential expression, so there is no single, correct way
to analyze the qPCR data.
Based on p-values with no adjustment, the results from the raw Ct values indicated that
BID, CPEB2, and LIN28A might be expressed at different levels in the success and failure
groups. Delta Ct data suggested CPEB2 and HSPA1A may have differential expression between
the groups. CPEB2 transcript levels were higher in the successful group than the failure group,
indicated by the lower Ct values in the success group. In contrast, BID, HSPA1A, and LIN28A
had higher average Ct values in the success group, meaning the genes tended to be expressed at
lower levels in the success group compared to the failure group. However, once FDR-corrected pvalues were considered, there were no statistically significant differences in transcript levels for
any of the genes for both data sets (raw Ct and delta Ct). Therefore, the differences detected for
the select few genes may not be sufficient to claim differential gene expression between the
success and failure groups.
One of the limitations of this study includes the imperfect control of the biopsy size. We
made an effort to control for this by excluding any oocytes that were abnormally small or large
and by relying on an expert to perform the biopsies through micromanipulation. We also analyzed
the data using delta Ct values, normalizing the data to a set of housekeeping genes, to address the
possibility of variation in biopsy sizes between samples. Another important limitation to this
project is that some variation between samples is unavoidable throughout the RNA extraction,
reverse transcription, and quantitative PCR protocols because the processes are not 100%
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efficient. However, we attempted to control for variation as much as possible by using the same
reagents, equipment, and protocols for all samples within an experiment as well as completing
each protocol in a short period of time to prevent degradation of samples.
A similar study, by Biase et al. (2014), also sought to identify differential expression in
transcripts between oocytes that successfully developed to the blastocyst stage and those that did
not by investigating cytoplasmic transcripts via biopsy. However, there are some important
differences between this previous study and ours. First, Biase et al. analyzed only embryos that
arrested between the 8- and 16-cell stage as their failed group, rather than using embryos arrested
at various stages before the blastocyst stage, as we did. Additionally, the study pooled biopsies
together in groups of 5 to form each replicate, resulting in a total of 5 replicates for the failure
group and 11 replicates for the successful, or blastocyst, group. Like in our study, Biase et al. also
compared blastocyst development rates between a biopsy and control group, as we did in
experiment 1. Similarly, their results support that a cytoplasmic biopsy of an oocyte did not
appear to impact developmental competency. The study found differential expression for 29
genes out of the 4,320 investigated. IGF2R was the only gene with differential expression that
was also included in our study. They observed higher levels of the transcript in the successful
group compared to the failure group (Biase, Everts et al. 2014), but our study did not indicate any
significant difference in transcript levels between the groups for IGF2R.
There are many other recent and ongoing studies focused on understanding oocyte quality
as well. One such study, by Zhang et al. (2020), compared mRNA levels using single-cell RNA
sequencing between metaphase II oocytes of younger women (under 30 years old) and older
women (over 40). They identified approximately 350 genes that were differentially expressed
between the age groups, with many of the genes involved in transcriptional activation, immunity,
and oxidative stress. Although the genes they identified are related to aging, perhaps some of the
genes are differentially expressed between high- and poor-quality oocytes, which in turn reflects
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age because oocyte quality decreases with age. If this were true, perhaps some bovine-equivalents
of the genes Zhang et al. (2016) identified would have been differentially expressed between the
successful and failed oocyte groups in our study, had they been included.
Additional studies have also investigated gene expression within cumulus cells and if that
expression may be indicative of oocyte quality. Bhardwaj et al. (2016) examined cumulus cells in
buffalo by staining cumulus oocyte complexes (COCs) with brilliant cresyl blue (BCB). The
COCs that had successfully completed growth and maturation retained the blue stain because they
had decreased G6PDH activity and could not break down the stain. Additionally, these COCs had
larger diameters and much higher IVF blastocyst rates compared to those that did not retain the
blue. The study also found significantly higher expression of GREM1, EGFR, and HAS2 mRNAs
in the cumulus cells of the mature COCs following qPCR, suggesting that these three mRNAs
could be biomarkers of oocyte quality (Bhardwaj, Ansari et al. 2016). Similarly, Green et al.
(2018) used RNA sequencing to compare gene expression in cumulus cells from sibling oocytes,
which were then developed into euploid blastocysts and transferred in pairs, between embryos
that resulted in live birth and those that did not. The study identified 132 genes that were
differentially expressed between the sibling embryos. However, like in our study, none of the
differences remained significant after correcting for the false discovery rate (Green, Franasiak et
al. 2018). Racowsky and Needleman (2018) described some of the limitations of the study done
by Green et al., pointing out that correction for multiple testing, although necessary for avoiding
false-positives, decreases the ability to find true positives in the data as well. Furthermore, they
argue that even though expression differences for the individual genes may not seem significant,
there is a possibility that the differences as a whole network of genes may add up to be more
meaningful (Racowsky and Needleman 2018). These principles could extend to our study results
too.
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While 48 genes was a significant number to analyze, it is still only approximately 0.2% of the
total genes in the bovine genome (Elsik, Tellam et al. 2009). Despite our best efforts to select
genes that we hypothesized would be meaningful markers of oocyte quality, it is possible that
we misjudged and selected genes and functional groups that are relatively unimportant to
oocyte developmental potential. Alternatively, it is possible that investigating differential mRNA
levels between oocytes as a reflection of quality is not the solution. For example, if oocytes
required transcript levels above or below a certain threshold for each gene but any variation
beyond that threshold did not influence oocyte quality, then it might be challenging to discern any
meaningful answers from transcript levels between groups of oocytes demonstrating successful
and failed development. Of course, there are also many other facets of oocyte maturation, such as
abundance of mitochondria, polyadenylation status of mRNAs, and/or phosphorylation status of
important cell signaling molecules (among others), that could alternatively be primary
determining factors in quality (Lechniak, Pers-Kamczyc et al. 2008). Future studies in these other
aspects of oocyte quality may offer some clarity.
In summary, we did not find any significant differences in transcript levels between the
success and failure group biopsies once correcting for false discovery rates. However, Experiment
1 and 2 were more conclusive and supported that a cytoplasmic biopsy of an oocyte does not
significantly impact potential for embryo development when oocytes are activated
parthenogenetically and that the 10% biopsy is highly representative of the remaining oocyte
cytoplasm in regards of transcripts. Despite having no significant findings concerning differential
expression between the biopsies corresponding to successful versus failed oocytes, this study
achieved significant technical advancements regarding the ability to quantitatively evaluate
transcript levels in micro-biopsies from individual MII oocytes, something that, to our
knowledge, has never been done before. Future studies, similar to ours, but with more samples, a
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larger scope of genes to investigate, and/or different functional categories of genes could
potentially reveal additional meaningful information pertaining to oocyte quality.
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